---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-122872"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2025-05-20T23:59:59+00:00"
generated_at: "2026-05-21T00:29:10.269153+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Rani Therapeutics induces warrant exercise by Armistice, receives ~$4.3M

## Summary
- Gross proceeds of ~$4.3M from cash exercise of Series B & C warrants at reduced exercise price of $0.65/sh.
- Issues new Series D warrant for 13,160,172 shares at $0.65/sh, 5-year term, subject to stockholder approval.
- Company must file resale registration statement for Series D shares within 45 days; seeks Nasdaq approval.
- Maxim Group receives 5.25% cash fee on gross proceeds as financial advisor.
- Proceeds to be used for working capital and general corporate purposes via Rani LLC.

## SEC filing metadata
- accession: 0001193125-25-122872
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2025-05-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000119312525122872/0001193125-25-122872-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000119312525122872/d945177d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-122872
- JSON: https://secwatch.observer/filing/0001193125-25-122872.json
- Plain text: https://secwatch.observer/filing/0001193125-25-122872.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.